Regulators push Amgen to withdraw drug due to data manipulation

Drug regulatory committees within the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are recommending that Amgen remove Tavneos (avacopan) from the market. An independent investigation – which concluded earlier this year – revealed that data from the drug’s phase 3 trial had previously been altered by staff of ChemoCentryx (the drug’s initial developers) to make the drug seem more effective. With the integrity of the research brought into question, the trial report has now been retracted.